Fractyl Health Inc (GUTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.64-6.60%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Fractyl Health aims to maintain cash through early 2027, securing operations. It targets key clinical milestones for its Revita and Rejuva therapies. The company recently beat earnings multiple times, showing some progress. A new CFO may improve management stability.
Fractyl Health is loss-making with volatile management and regulatory risks. It faces Nasdaq listing compliance issues and ongoing litigation. Earnings remain negative with no clear revenue growth yet. The stock is down 16.6% from its high.
The price is about 30% above our fair value of $0.61, reflecting some optionality but also elevated risk. The market expects modest growth but the company remains unprofitable and uncertain.
Breaks if: cash runway falls short of early 2027
Breaks if: failure to meet key clinical milestones in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a speculative growth category, focusing on a company that is currently loss-making but has potential clinical advancements. The current thesis is cautious, given the volatility in management and the high-risk nature of the business.
The market seems to be pricing in a low level of fragility, as no significant fragility gates have been triggered. However, GUTS trades at a premium compared to its peers, reflecting expectations for future growth driven by clinical developments.
Fundamentals may remain neutral in the near term, as management focuses on achieving key clinical milestones for Revita while managing cash burn. The company has shown some recent improvements in momentum and quality, but it still operates in a high-miss-rate industry.
The thesis hinges on several factors, including the ability to meet clinical milestones and maintain a cash runway into early 2027. Additionally, external influences like sector performance and economic conditions will play a significant role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company is on track for pivotal clinical data and FDA submission for Revita. However, it recently missed earnings expectations, which raises concerns.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance clinical development programs including pivotal data readouts and randomized data for weight maintenance indications.
Breaks if: failure to resolve Nasdaq compliance leading to delisting
Over the next 1 to 3 years, GUTS will need to navigate high risks while aiming for clinical success. The situation remains fluid, requiring close monitoring of developments. Not investment advice.